- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02500667
A Drug-Drug Interaction Study of N91115 +/- Rifampin in Healthy Adult Subjects
A Phase 1, Open-label, Drug-Drug Interaction Study to Assess the Steady State Pharmacokinetics of N91115 Alone and in the Presence of Multiple Dose Administration of Rifampin in Healthy Adult Subjects (SNO-5)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study will assess the effects of multiple oral dose administration of rifampin on the steady state plasma pharmacokinetics (PK) of N91115 in healthy subjects.
Eligible subjects (n=15) will receive oral doses of N91115 twice daily (approximately every 12 hours) on Study Days 1 through the morning of Day 13. On Study Days 8 through 12, rifampin administered 600 mg once daily will be added to the N91115 regimen. Study subjects will be monitored for safety while housed in the clinical research unit (CRU) until discharge on Day 14. Pharmacokinetics will be followed from Study Day 1 through Study Day 14. A follow-up phone call will be made on Day 20 (1 day). Participation of an individual subject may last up to approximately 48 days from the time of screening until the end-of-study follow-up call.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Colorado
-
Lakewood, Colorado, United States, 80228
- St. Anthony's Medical Plaza 1
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject voluntarily agrees to participate in this study; signs an IRB-approved informed consent
- Subject is healthy as determined by the screening medical evaluation (including but not limited to medical history, physical examination and clinical laboratory evaluations)
- Subject is Caucasian
- Female subject must be of non-childbearing potential or post-menopausal
- Male subject must agree to use a condom with spermicide and refrain from sperm donation from Day -1 until 30 days post last dose or have a vasectomy at least 6 months prior to screening
- Subject is a non-smoker
- Subject has a body weight > 45 kg and BMI between 18 and 32 kg/m2
- Subject has no clinically significant vital signs finding at screening or Day -1, per the investigator's judgment
- Subject has no clinically significant abnormal findings in 12-lead ECG , per the investigator's judgment, at screening
Exclusion Criteria:
- Subject has clinically significant history or evidence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, immunological, or psychiatric disorder(s)
- Subject has abnormal 12-lead ECG at screening per protocol
- Subject has any disorder that would interfere with the absorption, distribution, metabolism or excretion of drugs
- Subject has any concurrent disease or condition that, in the opinion of the investigator, would make the subject unsuitable for participation in the clinical study
- Subject is a current alcohol abuser and/or has a history of illicit drug abuse within 1 year prior to dosing
- Subject has a positive screening test for Hepatitis B surface antigen, Hepatitis C antibody, or human immunodeficiency virus (HIV) antibody
- Subject is unwilling to refrain from consumption of coffee and caffeine-containing foods and beverages from Day -1 until discharge on Day 14
- Subject is unwilling to abstain from using alcohol beverages from Day -1 until discharge on Day 14
- Subject has donated blood (> 500 mL) or blood products within 56 days prior to Day -1
- Subject has used over-the-counter (OTC) medications (including vitamins) from Day -7, or prescription medications, or herbal remedies from Day -14 until end-of-study follow-up call. By exception, acetaminophen ≤ 1000 mg/day is permitted except within 48 hours prior to Day -1 and hormone replacement therapy (HRT) is allowed throughout the study
- Subject has used an investigational drug within 30 days prior to Day 1 dosing
- Subject has a history of bleeding disorders
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: N91115 + Rifampin
N91115 200 mg twice daily (BID) from Study Day 1- 13, Rifampin 600 mg once daily (QD) from Study Day 8 - 12
|
600 mg QD
Other Names:
200 mg BID
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess the Potential Effects of Rifampin on N91115 Steady State Area Under the Curve (AUC) Values
Time Frame: On Study Day 14
|
To assess the effects of multiple oral dose administration of rifampin on the steady state AUC on Day 14 of N91115 in healthy subjects.
|
On Study Day 14
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effects of Rifampin on the AUC vs time of Metabolites of N91115
Time Frame: On Study Day 14
|
make a preliminary non statistical assessment on the effects of multiple oral dose administration of rifampin on steady state plasma PK of N91288 and metabolites, in healthy subjects
|
On Study Day 14
|
The number of participants with adverse events
Time Frame: Over the 21 days of the study
|
To evaluate the safety and tolerability of multiple oral doses of N91115 in the presence and absence of multiple oral doses of rifampin
|
Over the 21 days of the study
|
Effects of Rifampin on N91115 and its Metabolites on Urine 12 Hour drug concentrations
Time Frame: Day 14 assessment
|
To make a preliminary non statistical assessment on the effects of multiple oral dose administration of rifampin on the 12 hour steady state urine PK of N91115 and its primary metabolites in healthy subjects
|
Day 14 assessment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Christopher Galloway, MD, Davita Clinical Research
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-Bacterial Agents
- Leprostatic Agents
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 CYP3A Inducers
- Antitubercular Agents
- Antibiotics, Antitubercular
- Cytochrome P-450 CYP2B6 Inducers
- Cytochrome P-450 CYP2C8 Inducers
- Cytochrome P-450 CYP2C19 Inducers
- Cytochrome P-450 CYP2C9 Inducers
- Rifampin
Other Study ID Numbers
- N91115-1H-04 (SNO-5)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Drug Interaction Potentiation
-
Akebia TherapeuticsCompletedDrug Interaction PotentiationCanada
-
Il-Yang Pharm. Co., Ltd.CompletedDrug Interaction PotentiationKorea, Republic of
-
National Taiwan University HospitalCompletedDrug Interaction PotentiationTaiwan
-
Akebia TherapeuticsCompletedDrug Interaction PotentiationCanada
-
SK Chemicals Co., Ltd.CompletedDrug Interaction Potentiation
-
Tianjin Medical University General HospitalCompleted
-
Il-Yang Pharm. Co., Ltd.CompletedDrug Interaction PotentiationKorea, Republic of
-
F-star Therapeutics, Inc.PRA Health SciencesCompletedDrug Interaction PotentiationNetherlands
-
Akebia TherapeuticsCompletedDrug Interaction PotentiationCanada
-
LEO PharmaCompletedDrug Interaction PotentiationGermany
Clinical Trials on Rifampin
-
McGill University Health Centre/Research Institute...Canadian Institutes of Health Research (CIHR)Active, not recruitingLatent TuberculosisCanada, Indonesia, Vietnam
-
Pontificia Universidad Catolica de ChileSociedad Chilena de PediatríaUnknownRespiratory Distress SyndromeChile
-
Centre Hospitalier Universitaire, AmiensTerminatedAcute Respiratory Distress SyndromeFrance
-
Windtree TherapeuticsCompletedAcute Hypoxemic Respiratory FailureUnited States, Chile
-
CTI BioPharmaCovanceCompleted
-
Gangnam Severance HospitalCompletedAcinetobacter Infections | Colistin | Rifampin
-
Austin HealthCompletedHypersensitivity, Immediate | Hypersensitivity, Delayed | Hypersensitivity ResponseUnited States, Australia, Canada
-
Henry Ford Health SystemCompletedHidradenitis SuppurativaUnited States
-
Daping Hospital and the Research Institute of Surgery...Children's Hospital of Chongqing Medical UniversityRecruitingPreterm Birth | Acute Respiratory Distress Syndrome | Respiratory Distress Syndrome | Surfactant DysfunctionChina
-
Michael E. DeBakey VA Medical CenterBaylor College of MedicineCompletedStaphylococcus AureusUnited States